Related references
Note: Only part of the references are listed.Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
Emanuel Raschi et al.
TARGETED ONCOLOGY (2020)
2416PD1-blocking immune checkpoint inhibitor therapy for malignant melanoma induces left ventricular dysfunction
L Michel et al.
EUROPEAN HEART JOURNAL (2019)
Differences in clinical presentation and outcome between immune checkpoint inhibitor-associated myocarditis and classical acute myocarditis: Same disease, distinct challenges to face
Giacomo Veronese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma
Andres Chang et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients A meta-analysis of randomized clinical trials
Wei Wei et al.
MEDICINE (2017)
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
Daniel Y. Wang et al.
ONCOIMMUNOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
Christiane Michel et al.
CLINICAL DRUG INVESTIGATION (2017)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Disproportionality methods for pharmacovigilance in longitudinal observational databases
Ivan Zorych et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2013)
PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Margarite L. Tarrio et al.
JOURNAL OF IMMUNOLOGY (2012)
A brief primer on automated signal detection
M Hauben
ANNALS OF PHARMACOTHERAPY (2003)
Quantitative methods in pharmacovigilance - Focus on signal detection
M Hauben et al.
DRUG SAFETY (2003)
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
EP van Puijenbroek et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2002)
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
SJW Evans et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2001)
Share Paper
